Published in final edited form as:

Exp Mol Pathol. 2014 October ; 97(2): 234–240. doi:10.1016/j.yexmp.2014.07.001.

TLR3/4 Signaling is Mediated via the NF κ B-CXCR4/7 Pathway in Human Alcoholic Hepatitis and Non Alcoholic Steatohepatitis Which Formed Mallory-Denk Bodies

Hui Liu^a, Jun Li^a, Brittany Tillman^a, T Morgan^b, Barbara A. French^a, and Samuel W. French^{a,*}

^aLABioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA

^bVA Medical Center, Department of Medicine, Long Beach, CA, USA

Abstract

Activation of Toll-like receptor (TLR) signaling which stimulates inflammatory and proliferative pathways is the key element in the pathogenesis of Mallory-Denk bodies (MDBs) in mice fed DDC. However, little is known as to how TLR signaling is regulated in MDB formation during chronic liver disease development. The first systematic study of TLR signaling pathway transcript regulation in human archived formalin-fixed, paraffin-embedded (FFPE) liver biopsies with MDB formation is presented here. When compared to the activation of Toll-like signaling in alcoholic hepatitis (AH) and Non alcoholic steatohepatitis (NASH) patients, striking similarities and obvious differences were observed. Similar TLRs (TLR3 and TLR4, etc.), TLR downstream adaptors (MyD88 and TRIF, etc.) and transcript factors (NF κ B and IRF7, etc.) were all up regulated in the patients' livers. MyD88, TLR3 and TLR4 were significantly induced in the livers of AH and NASH compared to normal subjects, while TRIF and IRF7 mRNA were only slightly up regulated in AH patients. This is a different pathway from the induction of the TLR4-MyD88-independent pathway in the AH and NASH patients with MDBs present. Importantly, chemokine receptor 4 and 7 (CXCR4/7) mRNAs were found to be induced in the patients livers in FAT10 positive hepatocytes. The CXCR7 pathway was significantly up regulated in patients with AH and the CXCR4 was markedly up regulated in patients with NASH, indicating that CXCR4/7 is crucial in liver MDB formation. This data constitutes the first demonstration of the up regulation of the MyD88-dependent TLR4/NF κ B pathway in AH and NASH where MDBs formed, via the NF κ B-CXCR4/7 pathway, and provides further insight into the mechanism of MDB formation in human liver diseases.

© 2014 Elsevier Inc. All rights reserved.

*Corresponding author: Samuel W. French, Samuel W. French, MD, Department of Pathology, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90509, USA, Tel: +1-310-222-2643, Fax: +1-310-222-5333, sfrench@labiomed.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Toll-like receptor (TLR) signaling; Mallory-Denk bodies (MDBs); chemokine receptor 4 and 7 (CXCR4/7); MyD88-dependent pathway; liver disease development

Introduction

Mallory-Denk Bodies (MDBs), which are an intracellular deposition of misfolded protein in ballooned hepatocytes, consist of abnormally phosphorylated, ubiquitinated, and cross-linked keratins or non-keratin K18 and 8, and p62 components (Zatloukal *et al.*, 2007; Caldwell *et al.*, 2010; Basaranoglu *et al.*, 2011; Haybaeck *et al.*, 2012). Ballooning of hepatocytes is induced by oxidative stress, and both ballooning of hepatocytes and MDBs are two characteristics of ongoing inflammation (Basaranoglu *et al.*, 2011). MDBs are prevalent in various hepatic diseases including the hepatitis B and C virus (HBV and HCV), alcoholic hepatitis (AH), non-alcoholic steatohepatitis (NASH), drug injuries and hepatocellular carcinoma (HCC) (Zatloukal *et al.*, 2007; Basaranoglu *et al.*, 2011). Balloon hepatocytes forming MDBs are progenitor preneoplasia cells (French *et al.*, 2011). In the DDC fed mouse model where liver cells proliferate, MDBs form and later, after DDC withdrawal, HCCs develop (Oliva *et al.*, 2008). Three new mechanisms of MDB formation (epigenetic mechanisms, shift from the 26S proteasome to the immunoproteasome and activation of Toll-like signaling) have recently been identified (French *et al.*, 2010). However, the detailed molecular events involved in liver MDB formation, especially in human liver disease development, remains undetermined.

Toll-like receptors (TLRs) are a family of pattern-recognition receptors (PRRs) that play a critical role in chronic liver disease by recognizing pathogen-associated molecular patterns (PAMPs) (Roh & Seki, 2013). By recognizing corresponding ligands (bacteria, viruses, fungi, parasites, etc.), the TLRs signaling pathways are orchestrated via myeloid differentiation factor 88 (MyD88)-dependent or the TRIF-dependent pathway which initiates innate immune responses and priming antigen-specific acquired immunity (Takeuchi & Akira, 2010). Except for TLR3, all TLRs activate the MyD88-dependent pathway, recruit the IRAK family of protein kinases, and lead to the activation of TRAF6 (Akira & Takeda, 2004). TRAF6 induces the activation of the IKK complex and leads to activation of NF κ B, or activates AP-1 by TAK1 (Roh & Seki, 2013). In contrast, TLR3 and TLR4 can utilize the MyD88-independent, TRIF-dependent pathway. Subsequently, TRIF associates with TRAF 3 and TRAF 6 to activate the TBK1 and IKK complex, which results in the activation of interferon inducible genes and NF κ B respectively (Takeuchi & Akira, 2010). These transcription factors induce the expression of various inflammatory cytokines (TNF- α and IL-6, etc.), interferons, and chemokines. TLRs play key roles in the pathogenesis of a variety of liver diseases (Seki & Brenner, 2008), including the formation of HCC when mice are fed ethanol and LSP (French *et al.*, 2012; Machida *et al.*, 2012; Chen *et al.*, 2013). Activation of the resident liver cells, such as Kupffer cells, is one of the key elements in the pathogenesis of AH and NASH, producing inflammatory cytokines and chemokines to initiate the inflammatory cascade (Petrasek *et al.*, 2013a). Kupffer cells express all TLRs with the exception of TLR5 at mRNA and protein levels while hepatic stellate cells also express all

TLRs at transcriptional levels in quiescent and activated states (Wang *et al.*, 2009). Hepatocytes express all TLRs at the transcriptional level, while the expression levels of TLR2, TLR3, TLR4 and TLR5 are very low in vivo (Isogawa *et al.*, 2005) except in the Machida model (Machida *et al.*, 2009; Machida *et al.*, 2012). However, gene expression of Toll-signaling in ballooned hepatocytes (MDB-forming cells) is still unknown.

The Chemokine CXCL12 (SDF-1 α) is a broadly expressed CX chemokine, and the predominant CXCL12 receptor is the CX chemokine receptor 4 (CXCR4), a protein frequently over-expressed on the surface of human tumor cells of epithelial origin (Kaifi *et al.*, 2005; Schimanski *et al.*, 2005). CXCL12 can also bind another chemokine receptor CXCR7, which is present on the surface of many different malignant cell types (Burns *et al.*, 2006), and tumor-associated blood vessels (Miao *et al.*, 2007). Recently FAT10, which is over-expressed in various cancers including liver tumors (Lee *et al.*, 2003; Qing *et al.*, 2011), was found to activate NF κ B which in turn up regulates CXCR4/7 in NeHepLxHT and HCT116 cells (Gao *et al.*, 2014). This raises an interest for us to explore the relationship of NF κ B with CXCR4/7 induced by Toll-like signaling in liver patients with MDBs presents.

In this study, gene expression of TLRs signaling was investigated for the first time in the livers of AH and NASH patients' biopsies. Striking similarities and obvious differences in the activation of Toll-like signaling in AH and NASH patients were studied. Interestingly, CXCR4 and CXCR7 were both significantly up regulated in the patients' livers in FAT10 over-expressing hepatocytes.

Materials and Methods

Biopsies

Human archived formalin-fixed paraffin-embedded (FFPE) liver biopsies from patients who had alcoholic hepatitis (AH; n=3) and non-alcoholic steatohepatitis (NASH; n=3) were obtained from Harbor UCLA hospital archives. In all the cases liver forming MDBs were present except in the normal control livers (Control; n=3). The biopsy sections were cut 4 μ m thick.

RNA isolation and cDNA synthesis

RNA isolation of FFPE sections of human liver biopsies was performed as we previously described (Liu *et al.*, 2014). The quality and yield of the resulting total RNAs were assessed with an absorbance reading at 260 nm (A_{260}) using a spectrophotometer (Thermo). Synthesis of first-strand cDNAs was performed with the above mentioned total RNA (250ng), and random hexamer primers using SuperScript III First-Strand Synthesis SuperMix following the instruction (Invitrogen).

Quantitative Real-time PCR analysis

Real-time PCR was performed using the Fast SYBR Green Master Mix on a StepOnePlusTM Real-time PCR System (Applied Biosystems) with a primer concentration of 200 nM. Primer sequences and the related gene Accession Number are listed in Table I. Reaction

conditions consisted of 95°C for 20 sec, followed by 40 cycles of 95°C for 3 sec, 60 °C for 30 sec. Single PCR product was confirmed with the heat dissociation protocol at the end of the PCR cycles. Human α -tubulin was used as control to normalize the starting quantity of RNA. The target mRNA abundance in each sample was normalized to its endogenous control level and the relative mRNA expression levels were analyzed using the C_T method. Reaction of each sample was performed in triplicate.

Immunohistochemical staining

Formalin fixed, paraffin embedded tissue slides were double stained for CXCR4 (Abcam Inc., Cambridge MA) and Ubiquitin (Millipore, Temecula CA). A second set of slides was double stained for CXCR7 (Millipore, Temecula CA) and Ubiquitin (Millipore, Temecula, CA). CXCR4 and CXCR7 were detected using the second antibody donkey anti rabbit Alexa Fluor 488 (Jackson Immuno Research Laboratories Inc. West Grove, PA). Ubiquitin was detected using the second antibody donkey anti mouse Alexa Fluor 594 (Jackson Labs. West Grove, PA). All slides were stained with the nuclear stain DAPI (Molecular Probes, Eugene, OR). The slides were examined with a Nikon 400 fluorescent microscope.

Statistical analysis

Statistical significance was determined using the *t*-test and One Way ANOVA test with SigmaStat software. P values less than 0.05 were considered statistically significant. Regression plots were constructed using the Sigmaplot software. All data were presented as the mean $\pm$ S.E.M and were representative of at least two-independent experiments done in triplicate.

Results

TLR3 and TLR4 are significantly up regulated both in the livers of AH and NASH patients

An increased mRNA expression of TLR2 and TLR4 were observed in mice re-fed DDC (Bardag-Gorce *et al.*, 2010), implying the involvement of TLR signaling in liver MDB formation. To further examine how gene expression of Toll-like signaling was changed in human chronic liver diseases, where MDB formation progresses to tumor, TLRs were measured using real-time PCR analysis. Human liver biopsies, including normal liver tissue, AH and NASH biopsies were utilized in this assay. As expected, all TLRs mRNA tested were up regulated both in the livers of AH and NASH biopsies (Figure 1). Among them, approximately 3- and 7-fold (respectively, $p<0.05$) up regulation levels of TLR3 and TLR4 mRNAs were observed in the livers of AH biopsies when compare to other TLR mRNAs (Fig. 1A). In contrast to AH, TLR3 and TLR4 mRNAs were induced to 3- and 2.6-fold levels (respectively, $p<0.05$) in the livers of NASH patients (Fig. 1B). These results suggest that both TLR3 and TLR4 play an important role in the pathogenesis in AH and NASH patients. Other TLR mRNAs, including TLR2, TLR5 and TLR8, were also up regulated to various degrees in the livers of AH and NASH with MDBs present (Figure 1).

The MyD88-dependent pathways were markedly activated in the livers of both AH and NASH biopsies

Gene expression of TLRs signaling downstream molecules were further examined by real-time PCR analysis. Similar to some previous observations in mice (Bardag-Gorce *et al.*, 2010), the mRNA levels of MyD88, TRIF, IRAK1, IRAK4, TAK1, TRAF3, TRAF6 and IRF7 were all up regulated to various degrees in the AH patients liver biopsies (Fig. 2A). The MyD88 mRNA in the AH biopsies was induced by up to a 15-fold expression, while IRF3 mRNA showed almost no changes. This might suggest that the MyD88-dependent pathway is the main pathway in AH patients with MDBs present. In contrast to AH, mRNAs of MyD88, IRF3 and IRF7 were all significantly up regulated in the livers of NASH biopsies (Fig. 2B), suggesting both MyD88-dependent and MyD88-independent pathways are up regulated in the NASH patients. These results clearly indicated that MyD88-dependent pathway is markedly up regulated both in the livers of AH and NASH patients with MDB formation.

Liver MDB formation which may progress to HCC is involved in the NF κ B-CXCR4/7 pathway in FAT10 over-expression hepatocytes

Recent research showed that FAT10 is markedly up regulated in the livers of AH, cirrhosis and NASH biopsies with MDBs present (Liu *et al.*, 2014). FAT10 activates nuclear factor κ B (NF κ B), resulting in up regulation of the chemokine receptors CXCR4 and CXCR7 in NeHepLxHT cells (Gao *et al.*, 2014). Therefore, the mRNA levels of NF κ B p65, CXCR4 and CXCR7 were measured in the livers of AH and NASH biopsies by real-time PCR. As expected, the up regulation of mRNA expression of p65, CXCR4 and CXCR7 were observed in the patients' livers (Figure 3). Interestingly, the CXCR7 pathway was significantly up regulated in patients with AH and the CXCR4 and p65 expression were significantly up regulated in patients with NASH (Figure 3), indicating that CXCR4/7 plays a role in liver MDB formation. Immunohistochemical staining showed that MDB forming balloon hepatocytes in AH liver biopsies were expressing CXCR7 in the liver cytoplasm and co-localizing with ubiquitin in MDBs (Figure 4). These results indicate that the NF κ B-CXCR4/7 pathway is involved in liver MDB formation.

Discussion

Chronic liver disease such as alcoholic hepatitis (AH) and non-alcoholic steatohepatitis (NASH) represents a significant cause of morbidity and mortality worldwide (Burroughs & McNamara, 2003; Minino *et al.*, 2007). Recognition of Toll-like receptors (TLR) signaling, which produce inflammatory cytokines and chemokines to initiate the inflammatory cascade, is the key component involved in activation of innate immunity in AH and NASH (Petrasek *et al.*, 2013a). The TLR signaling pathways are up regulated in various chronic liver diseases. Different cell types in the liver express different TLRs (Seki *et al.*, 2011). TLR2 and TLR4 mRNA are also up regulated in the livers of DDC re-fed mice (Bardag-Gorce *et al.*, 2010) and in primary hepatocyte cultures where MDBs form (Yuan *et al.*, 2000; Nan *et al.*, 2005; Nan *et al.*, 2006). TLRs signaling are up regulated in rats fed ethanol intragastrically, especially when the blood alcoholic levels are high (Khachatoorian *et al.*,

2013). However, information about the pathologic significance of TLRs signaling in AH and NASH patients with MDBs present is still unknown.

To provide clinical evidence of gene expression of the TLRs signaling in the livers of AH and NASH patients with MDB-forming hepatocytes, biopsies from these patients were examined by real-time PCR analysis. An interesting observation is that the mRNA levels of TLR3 and TLR4 were much higher than other TLRs both in the livers of AH and NASH biopsies. Why TLR3 and TLR4 are significantly up regulated in the AH and NASH patients and what are the biological functions or mechanism of up regulation of these two TLRs in liver MDB formation? A possible reason is that TLR3 and TLR4 recognize different ligands where TLR3 recognizes viral double-strand RNA and poly (I: C) while TLR4 recognizes the endotoxin from Gram-negative bacteria, which can both induce an inflammatory response and antiviral immune response (Zhao *et al.*, 2008; Ganz & Szabo, 2013). Ample epidemiological evidence suggests that there is a strong connection between hepatitis C virus (HCV) and AH, where the prevalence of HCV is significantly higher among alcoholics than in the normal population (Heintges & Wands, 1997). Second, alcohol may enhance the replication of HCV and thus increase the expression of viral RNA and proteins, resulting in more severe HCV-induced liver injury (Brechot *et al.*, 1996). So the increase of viral RNA and protein levels might induce the up regulation expression of TLR3 mRNA to initiate the antiviral immune response. Additionally, we noticed that TLR7 and TLR8 whose ligands are viral single-stranded RNA, were also slightly up regulated in AH biopsies.

The activation of both MyD88-dependent and MyD88-independent pathways were reported in mouse models of AH and NASH (Hritz *et al.*, 2008; Csak *et al.*, 2011a). The downstream molecules of TLRs in AH and NASH were further investigated by real-time PCR analysis. A significantly up regulated expression of MyD88 mRNA (15 fold, $p < 0.05$) was observed in the livers of AH patients, indicating that the MyD88-dependent pathway was activated. To understand liver tumorigenesis, it is very important to analyze which cell types are involved in the process. Kupffer cells may be the major cells expressing TLRs in the liver (Roh & Seki, 2013). A recent study showed that TLR4 signaling in AH is mediated via the TRIF/IRF3-dependent, MyD88-independent pathway using the Lieber-DeCarli model of AH (Petrasek *et al.*, 2013b). However, we did not observe the obvious changes of IRF3 and IRF7 mRNA, nor TRIF mRNA in the livers of AH biopsies. Our observation suggests that the MyD88-dependent pathway is the main pathway in AH patients with MDBs present, different from the observation in Kupffer cells. The possible cause may be the differences of cell types involved, since all cases studied by immunohistochemistry showed an increased expression of TLR4 in the cytoplasm of the liver cells (Lee *et al.*, 2014), including the balloon cells forming MDBs, and including incorporation of TLR4 within the MDB. We also noticed that the mRNA level of TLR4 was higher than TLR3 in the livers of AH patients, probably suggesting that inflammatory response is the main pathway involved compared to antivirus immune response in the hepatocytes.

It was observed that MyD88, IRF3 and IRF7 mRNAs were all significantly up regulated in the livers of NASH biopsies, which was different from AH. Also it was noted that the mRNA level of TLR3 is slightly higher than TLR4 in the livers of NASH patients, indicating both TLR4 MyD88-dependent and TLR3 MyD88-independent pathways were

activated in the pathogenesis of NASH development in MDB formation. The differential induction of MyD88-dependent and MyD88-independent pathway in AH and NASH patients may relate to the differences in dynamics between these two disease (Petrasek *et al.*, 2013a). This is because excessive consumption of alcohol may induce liver inflammation in a shorter period of time than the consumption of a steatogenic diet, which results in the development of NASH (Csak *et al.*, 2011a; Csak *et al.*, 2011b). Secondly, the development of NASH involves insulin resistance and an endocrine crosstalk between adipose tissue and the liver, which inhibits the TLR4/MyD88-dependent pathway in macrophages (Mandal *et al.*, 2010). However, it is still uncertain as to how adiponectin, an anti-inflammatory cytokine secreted by adipose tissue, contributes to the MyD88-dependent pathways of NASH in MDB-forming hepatocytes. Strangely, we did not observe the significant up regulation of TRIF mRNA in the livers of AH and NASH patients, although there was a marked increase of IRF3 and IRF7 mRNAs in the livers of NASH biopsies.

After activation by ligands, TLRs triggers a cascade of downstream adaptor signaling and ultimately activate the transcription factors NF κ B and chemokines. The chemokine CXCL12 appears to be of particular importance in tumor biology, and interaction of CXCL12 with its receptor CXCR4 and CXCR7 is found to be highly expressed in tumor and tumor-endothelial cells (Miao *et al.*, 2007; Burger & Peled, 2009; Hattermann *et al.*, 2010). The CXCL12/CXCR4 and CXCL12/CXCR7 axis are important factors in tumor initiation, promotion, progression, metastasis and cancer cell survival (Vandercappellen *et al.*, 2008; Marechal *et al.*, 2009). However, the biological significance of CXCR4 and CXCR7 in liver MDB-forming cells is still unknown. Therefore, the transcript regulation of CXCR4 and CXCR7, with NF κ B p65 were investigated by real-time PCR analysis in the livers of AH and NASH biopsies. In our series, CXCR4 mRNA was significantly up regulated in patients with NASH, while CXCR7 mRNA was significantly up regulated in the patients with AH, suggesting a different role played by these two receptors in NASH and AH. The reasons for the differences between CXCR4 and CXCR7 mRNA levels in AH and NASH patients probably result from CXCR4 and CXCR7 having different CXCL12 binding domains and distinct roles during disease development (Sierro *et al.*, 2007), although both of them can bind to CXCL12. Another reason may be because unlike CXCR4, CXCL12 activation of CXCR7 does not induce calcium mobilization and cell migration but rather results in a proliferative effect and increased adhesion properties (Burns *et al.*, 2006; Wang *et al.*, 2008). Although we observed the differential expression of CXCR4 and CXCR7 in the livers of AH and NASH patients, whether they are involved in MDB-forming hepatocytes needs to be determined.

Recently, we observed the marked up regulation expression of FAT10 in the livers of AH and NASH patients (Liu *et al.*, 2014). FAT10 expression is induced by interferon (IFN)- γ and tumor necrosis factor α (TNF α) in tumor cells (Lukasiak *et al.*, 2008; Ren *et al.*, 2011) and activates NF κ B, which in turn up regulates CXCR4/7 in NeHepLxHT and HCT116 cells (Gao *et al.*, 2014). Interestingly, the NF κ B binding site was found at the FAT10 promoter region (Zhang *et al.*, 2006), while TNF α -dependent induction of FAT10 expression requires NF κ B activation (Ren *et al.*, 2011). The interferon sequence response element (ISRE) located on the FAT10 promoter region activates NF κ B in response to IFN γ .

(Oliva *et al.*, 2010). These findings indicate a potential feedback system in chronic inflammatory-associated microenvironments such as in AH and NASH. The cytokine TNF- α or chemokines induced by the activation of TLRs signaling induce FAT10, which activates NF κ B. This in turn promotes the FAT10 transcription by binding to FAT10 promoter sites (Oliva *et al.*, 2010). NF κ B has recently been found to bind a transcript factor for both CXCR4 and CXCR7 receptors (Tarnowski *et al.*, 2010), and CXCR4 and CXCR7 can also activate NF κ B (Huang *et al.*, 2009), further suggesting CXCR4 and CXCR7 may sustain NF κ B activity by a feedback system. We confirmed that the CXCR4 and CXCR7 mRNAs were up regulated in MDB-forming (FAT10-over-expressing) hepatocytes within this NF κ B network. Based on these findings, transcription up regulation of TLR signaling and CXCR4/7 which results in liver MDB formation is shown in Figure 5. The gene expression changes induced by TLR signaling, inducing the up regulation of FAT10 and CXCR4/7, may be a novel mechanism in liver MDB formation. The further elucidation of the relationship of FAT10 and CXCR4/7 in the inflammatory pathway including TLR pathway will provide a better understanding of chronic liver disease pathogenesis and MDB formation.

In summary, our data demonstrates for the first time the gene expression changes of TLR signaling in the livers of AH and NASH patients where MDBs formed. Striking similarities and obvious differences were observed in the TLR signaling activation, where the MyD88-dependent pathway was significantly up regulated in patients with AH, while both MyD88-dependent and MyD88-independent pathways were up regulated in patients with NASH. The prominent transcription up regulation expression of CXCR4 and CXCR7 were observed in FAT10 over expressing hepatocytes, indicating that CXCR4 and CXCR7 may be attractive targets for AH and NASH therapy. The data provide evidence to further understand human liver disease and MDB formation.

Acknowledgments

This work was supported by grants from NIH (AAU01021898-02) and P50-11999 Morphology Core. Some results were submitted in a Poster Abstract (2027981) in AASLD LIVER MEETING Nov 2014, BOSTON

Abbreviations

AH	alcoholic hepatitis
CXCR4/7	Human chemokine (C-X-C motif) receptor 4/7
DDC	diethyl 1, 4-dehydro-2, 4, 6-trimethyl-3, 5-pyridine-dicarboxylate
FFPE	formalin-fixed, paraffin-embedded
HCC	hepatocellular carcinoma
MDB	Mallory-Denk body
MyD88	Myeloid differentiation primary response gene 88
NASH	non-alcoholic steatohepatitis
TLR	Toll-like receptor

References

- Akira S, Takeda K. Toll-like receptor signalling. *Nat Rev Immunol*. 2004; 4:499–511. [PubMed: 15229469]
- Bardag-Gorce F, Oliva J, Lin A, Li J, French BA, French SW. SAME prevents the up regulation of toll-like receptor signaling in Mallory-Denk body forming hepatocytes. *Exp Mol Pathol*. 2010; 88:376–379. [PubMed: 20206621]
- Basaranoglu M, Turhan N, Sonsuz A, Basaranoglu G. Mallory-Denk Bodies in chronic hepatitis. *World J Gastroenterol*. 2011; 17:2172–2177. [PubMed: 21633525]
- Brechot C, Nalpas B, Feitelson MA. Interactions between alcohol and hepatitis viruses in the liver. *Clin Lab Med*. 1996; 16:273–287. [PubMed: 8792072]
- Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. *Leukemia*. 2009; 23:43–52. [PubMed: 18987663]
- Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. *J Exp Med*. 2006; 203:2201–2213. [PubMed: 16940167]
- Burroughs A, McNamara D. Liver disease in Europe. *Aliment Pharmacol Ther*. 2003; 18(Suppl 3):54–59. [PubMed: 14531742]
- Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, Pramoonjago P, Simmons W, Scruggs H, Rosenbaum N, Wilkinson T, Toms P, Argo CK, Al-Osaimi AM, Redick JA. Hepatocellular ballooning in NASH. *J Hepatol*. 2010; 53:719–723. [PubMed: 20624660]
- Chen CL, Tsukamoto H, Liu JC, Kashiwabara C, Feldman D, Sher L, Dooley S, French SW, Mishra L, Petrovic L, Jeong JH, Machida K. Reciprocal regulation by TLR4 and TGF-beta in tumor-initiating stem-like cells. *J Clin Invest*. 2013; 123:2832–2849. [PubMed: 23921128]
- Csak T, Dolganiuc A, Kodys K, Nath B, Petrasek J, Bala S, Lippai D, Szabo G. Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice. *Hepatology*. 2011a; 53:1917–1931. [PubMed: 21425308]
- Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. *Hepatology*. 2011b; 54:133–144. [PubMed: 21488066]
- French SW, Bardag-Gorce F, French BA, Li J, Oliva J. The role of innate immunity in the pathogenesis of preneoplasia in drug-induced chronic hepatitis based on a mouse model. *Exp Mol Pathol*. 2011; 91:653–659. [PubMed: 21820428]
- French SW, Bardag-Gorce F, Li J, French BA, Oliva J. Mallory-Denk body pathogenesis revisited. *World J Hepatol*. 2010; 2:295–301. [PubMed: 21161012]
- French SW, Lee J, Zhong J, Morgan TR, Buslon V, Lungu W, French BA. Alcoholic liver disease - Hepatocellular carcinoma transformation. *J Gastrointest Oncol*. 2012; 3:174–181. [PubMed: 22943009]
- Ganz M, Szabo G. Immune and inflammatory pathways in NASH. *Hepatol Int*. 2013; 7:771–781. [PubMed: 24587847]
- Gao Y, Theng SS, Zhuo J, Teo WB, Ren J, Lee CG. FAT10, an ubiquitin-like protein, confers malignant properties in non-tumorigenic and tumorigenic cells. *Carcinogenesis*. 2014; 35:923–934. [PubMed: 24325913]
- Hattermann K, Held-Feindt J, Lucius R, Muerkoster SS, Penfold ME, Schall TJ, Mentlein R. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. *Cancer Res*. 2010; 70:3299–3308. [PubMed: 20388803]
- Haybaeck J, Stumptner C, Thueringer A, Kolbe T, Magin TM, Hesse M, Fickert P, Tsybrovskyy O, Muller H, Trauner M, Zatloukal K, Denk H. Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. *Lab Invest*. 2012; 92:857–867. [PubMed: 22449798]
- Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. *Hepatology*. 1997; 26:521–526. [PubMed: 9303478]

- Hritz I, Mandrekar P, Velayudham A, Catalano D, Dolganiuc A, Kodys K, Kurt-Jones E, Szabo G. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. *Hepatology*. 2008; 48:1224–1231. [PubMed: 18792393]
- Huang CY, Lee CY, Chen MY, Yang WH, Chen YH, Chang CH, Hsu HC, Fong YC, Tang CH. Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. *J Cell Physiol*. 2009; 221:204–212. [PubMed: 19496172]
- Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. *J Virol*. 2005; 79:7269–7272. [PubMed: 15890966]
- Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbic JR. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. *J Natl Cancer Inst*. 2005; 97:1840–1847. [PubMed: 16368946]
- Khachatoorian R, Dawson D, Maloney EM, Wang J, French BA, French SW. SAME treatment prevents the ethanol-induced epigenetic alterations of genes in the Toll-like receptor pathway. *Exp Mol Pathol*. 2013; 94:243–246. [PubMed: 23047067]
- Lee CG, Ren J, Cheong IS, Ban KH, Ooi LL, Yong Tan S, Kan A, Nuchprayoon I, Jin R, Lee KH, Choti M, Lee LA. Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. *Oncogene*. 2003; 22:2592–2603. [PubMed: 12730673]
- Lee J, French B, Morgan T, French SW. The liver is populated by a broad spectrum of markers for macrophages. In alcoholic hepatitis the macrophages are M1 and M2. *Exp Mol Pathol*. 2014; 96:118–125. [PubMed: 24145004]
- Liu H, Li J, Tillman B, French BA, French SW. Ufmylation and FATylation pathways are downregulated in human alcoholic and nonalcoholic steatohepatitis, and mice fed DDC, where Mallory-Denk bodies (MDBs) form. *Exp Mol Pathol*. 2014; 97:81–88. [PubMed: 24893112]
- Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K, Groettrup M. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. *Oncogene*. 2008; 27:6068–6074. [PubMed: 18574467]
- Machida K, Chen CL, Liu JC, Kashiwabara C, Feldman D, French SW, Sher L, Hyeongnam JJ, Tsukamoto H. Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus. *J Gastroenterol Hepatol*. 2012; 27(Suppl 2):19–22. [PubMed: 22320911]
- Machida K, Tsukamoto H, Mkrtchyan H, Duan L, Dynnyk A, Liu HM, Asahina K, Govindarajan S, Ray R, Ou JH, Seki E, Deshaies R, Miyake K, Lai MM. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. *Proc Natl Acad Sci U S A*. 2009; 106:1548–1553. [PubMed: 19171902]
- Mandal P, Roychowdhury S, Park PH, Pratt BT, Roger T, Nagy LE. Adiponectin and heme oxygenase-1 suppress TLR4/MyD88-independent signaling in rat Kupffer cells and in mice after chronic ethanol exposure. *J Immunol*. 2010; 185:4928–4937. [PubMed: 20861358]
- Marechal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Deviere J, Salmon I, Van Laethem JL. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. *Br J Cancer*. 2009; 100:1444–1451. [PubMed: 19352387]
- Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. *Proc Natl Acad Sci U S A*. 2007; 104:15735–15740. [PubMed: 17898181]
- Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. *Natl Vital Stat Rep*. 2007; 55:1–119. [PubMed: 17867520]
- Nan L, Dedes J, French BA, Bardag-Gorce F, Li J, Wu Y, French SW. Mallory body (cytokeratin aggregates) formation is prevented in vitro by p38 inhibitor. *Exp Mol Pathol*. 2006; 80:228–240. [PubMed: 16563375]
- Nan L, Wu Y, Bardag-Gorce F, Li J, French BA, Wilson LT, French SW. The p105/50 NF-kappaB pathway is essential for Mallory body formation. *Exp Mol Pathol*. 2005; 78:198–206. [PubMed: 15924871]

- Oliva J, Bardag-Gorce F, French BA, Li J, McPhaul L, Amidi F, Dedes J, Habibi A, Nguyen S, French SW. Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis. *Exp Mol Pathol.* 2008; 84:102–112. [PubMed: 18280469]
- Oliva J, Bardag-Gorce F, Lin A, French BA, French SW. The role of cytokines in UbD promoter regulation and Mallory-Denk body-like aggresomes. *Exp Mol Pathol.* 2010; 89:1–8. [PubMed: 20433827]
- Petrasek J, Csak T, Ganz M, Szabo G. Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis. *J Gastroenterol Hepatol.* 2013a; 28(Suppl 1):93–98. [PubMed: 23855302]
- Petrasek J, Iracheta-Vellve A, Csak T, Satishchandran A, Kodys K, Kurt-Jones EA, Fitzgerald KA, Szabo G. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. *Proc Natl Acad Sci U S A.* 2013b; 110:16544–16549. [PubMed: 24052526]
- Qing X, French BA, Oliva J, French SW. Increased expression of FAT10 in colon benign, premalignant and malignant epithelial neoplasms. *Exp Mol Pathol.* 2011; 90:51–54. [PubMed: 20888811]
- Ren J, Wang Y, Gao Y, Mehta SB, Lee CG. FAT10 mediates the effect of TNF-alpha in inducing chromosomal instability. *J Cell Sci.* 2011; 124:3665–3675. [PubMed: 22025632]
- Roh YS, Seki E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. *J Gastroenterol Hepatol.* 2013; 28(Suppl 1):38–42. [PubMed: 23855294]
- Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V, Junginger T, Berger MR, Galle PR, Moehler M. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. *Clin Cancer Res.* 2005; 11:1743–1750. [PubMed: 15755995]
- Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. *Hepatology.* 2008; 48:322–335. [PubMed: 18506843]
- Seki E, Park E, Fujimoto J. Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis. *Hepatol Res.* 2011; 41:597–610. [PubMed: 21696522]
- Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, Woehl B, Leung H, Groom J, Batten M, Harvey RP, Martinez AC, Mackay CR, Mackay F. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. *Proc Natl Acad Sci U S A.* 2007; 104:14759–14764. [PubMed: 17804806]
- Takeuchi O, Akira S. Pattern recognition receptors and inflammation. *Cell.* 2010; 140:805–820. [PubMed: 20303872]
- Tarnowski M, Grymula K, Reza R, Jankowski K, Maksym R, Tarnowska J, Przybylski G, Barr FG, Kucia M, Ratajczak MZ. Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. *Mol Cancer Res.* 2010; 8:1–14. [PubMed: 20068066]
- Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. *Cancer Lett.* 2008; 267:226–244. [PubMed: 18579287]
- Wang B, Trippler M, Pei R, Lu M, Broering R, Gerken G, Schlaak JF. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. *J Hepatol.* 2009; 51:1037–1045. [PubMed: 19716616]
- Wang J, Shiozawa Y, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. *J Biol Chem.* 2008; 283:4283–4294. [PubMed: 18057003]
- Yuan QX, Nagao Y, French BA, Wan YJ, French SW. Dexamethasone enhances mallory body formation in drug-primed mouse liver. *Exp Mol Pathol.* 2000; 69:202–210. [PubMed: 11115361]
- Zatloukal K, French SW, Stumptner C, Strnad P, Harada M, Toivola DM, Cadrin M, Omary MB. From Mallory to Mallory-Denk bodies: what, how and why? *Exp Cell Res.* 2007; 313:2033–2049. [PubMed: 17531973]
- Zhang DW, Jeang KT, Lee CG. p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. *Oncogene.* 2006; 25:2318–2327. [PubMed: 16501612]

Zhao XJ, Dong Q, Bindas J, Piganelli JD, Magill A, Reiser J, Kolls JK. TRIF and IRF-3 binding to the TNF promoter results in macrophage TNF dysregulation and steatosis induced by chronic ethanol. *J Immunol.* 2008; 181:3049–3056. [PubMed: 18713975]

Figure 1.

Gene expression of TLRs signaling in the livers of AH and NASH biopsies. mRNA levels of different TLRs in the livers of AH (A) and NASH (B) biopsies are shown. Data represents mean values $\pm$ S.E.M. Statistical significance was determined using the *t*-test with SigmaStat software. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ by *t*-test.

Figure 2.

Induction of TLRs downstream components in the livers of AH (A) and NASH (B) biopsies. Quantification of mRNA was carried out by SYBR real-time PCR assays. * $p < 0.05$ by t -test with SigmaStat software.

Figure 3.

Gene transcript expression of human p65, CXCR4 and CXCR7 in patient livers from human archived biopsies with AH, NASH and normal liver tissue. Data represent mean values $\pm$ S.E.M. * $p < 0.05$ by *t*-test with SigmaStat software.

Fig. 4.
IHC double stain of Alcoholic Hepatitis biopsy compared to Control Liver showing positive staining of CXCR7 (A-FITC) including MDB positive Balloon hepatocytes (Texas Red and Tricolor) compared to Control x 606

Figure 5.

Proposed model of gene expression up regulation of TLR signaling and CXCR4/7 in human liver MDB formation. Alcoholic hepatitis (AH) and non-alcoholic steatohepatitis (NASH) transcript up regulation of TLR signaling activation and CXCR4/7 are presented.

Table I

Sequences of the forward and reverse real-time PCR primers of human TLR signaling

Gene name (Species)	Accession Number	Sequences of primer
TLR1 (Human)	NM_003263	Forward Primer: 5'-ATT CCG CAG TAC TCC ATT CC-3' Reverse Primer: 5'-TTT GCT TGC TCT GTC AGC TT -3'
TLR2 (Human)	NM_003264	Forward Primer: 5'-ATG CCT ACT GGG TGG AGA AC -3' Reverse Primer: 5'-TGC ACC ACT CAC TCT TCA CA -3'
TLR3 (Human)	NM_003265	Forward Primer: 5'-GAA AGG CTA GCA GTC ATC CA -3' Reverse Primer: 5'-CAT CGG GTA CCT GAG TCA AC -3'
TLR4 (Human)	NM_138554	Forward Primer: 5'-CAG CTC TTG GTG GAA GTT GA -3' Reverse Primer: 5'-GCA AGA AGC ATC AGG TGA AA -3'
TLR5 (Human)	NM_003268	Forward Primer: 5'-GGA ACC AGC TCC TAG CTC CT -3' Reverse Primer: 5'-AAG AGG GAA ACC CCA GAG AA -3'
TLR7 (Human)	NM_016562	Forward Primer: 5'-TTG CAA AAC ACA ACT GCC TA -3' Reverse Primer: 5'-AAA CCC CAT CTT TCC AAC TC -3'
TLR8 (Human)	NM_138636	Forward Primer: 5'-GGG CAT TGC ATT TAA GAG GT -3' Reverse Primer: 5'-TCC GGA TAT GAC GTT GAA AA -3'
TLR9 (Human)	NM_017442	Forward Primer: 5'-CTG CGA GAG CTC AAC CTT AG -3' Reverse Primer: 5'-CTC CAG CAG GAA GTC CAT AA -3'
MyD88 (Human)	NM_002468	Forward Primer: 5'-GCA CAT GGG CAC ATA CAG AC -3' Reverse Primer: 5'-GAC ATG GTT AGG CTC CCT CA -3'
TRIF (Human)	NM_182919	Forward Primer: 5'-GGA ATC ATC ATC GGA ACA GA-3' Reverse Primer: 5'-TCG AAG TTG GAG GTG AGA AG-3'
IRAK1 (Human)	NM_001569	Forward Primer: 5'-CCA AAC ATT GTG GAC TTT GC -3' Reverse Primer: 5'-GGC TGT ACC CAG AAG GAT GT -3'
IRAK4 (Human)	NM_001114182	Forward Primer: 5'-CTG AGG CAG GAG ACT AGC TG -3' Reverse Primer: 5'-AAT GTG GGC AAA ACC TGT AA -3'
TAK1 (Human)	NM_003188	Forward Primer: 5'-AGA GGA GCC TTT GGA GTT GT-3' Reverse Primer: 5'-CCA TCA CAA GAC ACA CTG GA-3'
TRAF3 (Human)	NM_145725	Forward Primer: 5'-CAG AGG TTG TGC AGA GCA GT -3' Reverse Primer: 5'-CCG GTA TTT ACA CGC CTT CT -3'
TRAF6 (Human)	NM_145803	Forward Primer: 5'-GGA AGA TTG GCA ACT TTG GA -3' Reverse Primer: 5'-CGT GGT TTT GCC TTA CAG GT -3'
IRF3 (Human)	NM_001571	Forward Primer: 5'-TCG AGG TGA CAG CCT TCT AC -3' Reverse Primer: 5'-GCC TCA CGT AGC TCA TCA CT -3'
IRF7 (Human)	NM_001572	Forward Primer: 5'-TAC CAT CTA CCT GGG CTT CG -3' Reverse Primer: 5'-GCT CCA TAA GGA AGC ACT CG -3'
CXCR4 (Human)	NM_001008540	Forward Primer: 5'-GGT GGT CTA TGT TGG CGT CT -3' Reverse Primer: 5'-TGG AGT GTG ACA GCT TGG AG -3'
CXCR7 (Human)	NM_020311	Forward Primer: 5'-TCT GGG ACG GGT TTA CTT GT -3' Reverse Primer: 5'-CTG CCT GTT GCA AAA CTG TC -3'
P65 (Human)	NM_021975	Forward Primer: 5'-CTC TGC TTC CAG GTG ACA GT -3' Reverse Primer: 5'-TCC TCT TTC TGC ACC TTG TC -3'